文献速递产科母胎医学

妊娠期与哺乳期女性药物研发研究

Drug development research in pregnant and lactating women.
PubMed 文献 · Am J Obstet Gynecol · 2021-04-19

妊娠期和哺乳期女性因法律、伦理和安全顾虑长期被排除在临床药物研究和药物开发过程之外,被视为「治疗孤儿」,多数用于她们的药物为超说明书用药。本文综述了产科-胎儿药理学研究单位网络已研究的药物,讨论当前产科药理学研究的挑战及精准治疗研究的替代策略。

要点

  • 妊娠期和哺乳期女性多被排除在药物临床试验之外,多数用药为超说明书用药。
  • 缺乏妊娠期和哺乳期人体安全数据的药物可能给母婴带来不良效应和致畸风险。
  • 「共同规则」修订将孕妇从「脆弱」人群分类中移除,可能改变药物研发文化。

核心结论

  • 妊娠期和哺乳期女性长期被排除在临床药物研究和药物开发之外,多数用药缺乏妊娠期和哺乳期标签信息而属超说明书用药。
  • 「共同规则」修订将孕妇从「脆弱」人群分类中移除,可能改变妊娠期和哺乳期女性药物研究的文化。
  • 实施妊娠期和哺乳期女性专门研究工作组的建议可为相关研究提供立法要求和机会。

研究设计与样本

  • 本文为综述,概述产科-胎儿药理学研究单位网络与中心已研究的药物。
  • 文章描述当前产科药理学研究的挑战及妊娠期和哺乳期女性精准治疗的未来研究替代策略。

主要发现

  • 多数获临床批准的药物缺乏适用于妊娠期和哺乳期女性的标签信息。
  • 缺乏妊娠期和哺乳期人体安全数据的药物可能对妊娠期和哺乳期女性产生不良效应,并对其未出生和新生儿婴儿有致畸风险。
  • 联邦政策要求将女性纳入临床研究和试验,使研究设计与实践发生显著变化。
  • 尽管更多女性被纳入临床研究和试验,妊娠期和哺乳期女性在药物研究和临床试验中的纳入仍然有限。

临床怎么用

  • 应重视妊娠期和哺乳期女性药物安全数据的缺乏及超说明书用药现状。
  • 可参考产科-胎儿药理学研究单位网络与中心的研究经验及工作组建议推动相关研究。

局限性

  • 本文为综述,未报告具体研究样本量、效应值或统计学检验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pregnant and lactating women are considered "therapeutic orphans" because they generally have been excluded from clinical drug research and the drug development process owing to legal, ethical, and safety concerns. Most medications prescribed for pregnant and lactating women are used "off-label" because most of the clinical approved medications do not have appropriate drug labeling information for pregnant and lactating women. Medications that lack human safety data on use during pregnancy and lactation may pose potential risks for adverse effects in pregnant and lactating women as well as risks of teratogenic effects to their unborn and newborn babies. Federal policy requiring the inclusion of women in clinical research and trials led to considerable changes in research design and practice. Despite more women being included in clinical research and trials, the inclusion of pregnant and lactating women in drug research and clinical trials remains limited. A recent revision to the "Common Rule" that removed pregnant women from the classification as a "vulnerable" population may change the culture of drug research and drug development in pregnant and lactating women. This review article provides an overview of medications studied by the Obstetric-Fetal Pharmacology Research Units Network and Centers and describes the challenges in current obstetrical pharmacology research and alternative strategies for future research in precision therapeutics in pregnant and lactating women. Implementation of the recommendations of the Task Force on Research Specific to Pregnant Women and Lactating Women can provide legislative requirements and opportunities for research focused on pregnant and lactating women.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Ren Z, Bremer AA, Pawlyk AC, et al. Drug development research in pregnant and lactating women. Am J Obstet Gynecol. 2021. PMID: 33887238. doi:10.1016/j.ajog.2021.04.227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。